Long-term efficacy and safety of intramuscular interferon beta-1a: Randomized postmarketing trial of two dosing regimens in Japanese patients with relapsing-remitting multiple sclerosis
详细信息 查看全文
- 作者：Takahiko Saidaa ; Saida_takahiko@maia.eonet.ne.jp" class="auth_mail" title="E-mail the corresponding author ; Jun-ichi Kirab ; kira@neuro.med.kyushu-u.ac.jp" class="auth_mail" title="E-mail the corresponding author ; Yasuhiro Uenoc ; yasuhiro.ueno@biogen.com" class="auth_mail" title="E-mail the corresponding author ; Naozumi Haradac ; nysharad@gmail.com" class="auth_mail" title="E-mail the corresponding author ; Toshiyuki Hirakatac ; toshiyuki.hirakata@biogen.com" class="auth_mail" title="E-mail the corresponding author
- 关键词：ARR ; annualized relapse rate ; CI ; confidence interval ; EDSS ; Expanded Disability Status Scores ; Gd+ ; gadolinium-enhancing ; IFN beta ; interferon beta ; IFN beta-1a ; interferon beta-1a ; IM ; intramuscular ; MedDRA ; Medical Dictionary for Regulatory Activities ; MRI ; magnetic resonance imaging ; MS ; multiple sclerosis ; MSCRG ; Multiple Sclerosis Collaborative Research Group ; RRMS ; relapsing remitting multiple sclerosis ; SD ; standard deviation
- 刊名：Multiple Sclerosis and Related Disorders
- 出版年：2016
- 出版时间：May 2016
- 年：2016
- 卷：7
- 期：Complete
- 页码：102-108
- 全文大小：489 K
文摘
- •
Phase IV study of IFN beta-1a (30 mcg/week) in Japanese patients with RRMS.
- •
ARR decreased and EDSS score improved during the 2-year treatment period.
- •
There were no new safety concerns noted during the study.
- •
Dose titration slightly reduced influenza-like symptoms at early timepoints.
- •
IFN beta-1a can be used effectively and safely in Japanese patients with RRMS.